Guidelines for Management of Hypothalamic-Pituitary, Growth Disorders in Childhood Cancer Survivors
Data indicate that up to half of all children who survive cancer will develop an endocrine disorder during their lifetime.
A clinical practice guideline that addresses the diagnosis and treatment of hypothalamic–pituitary and growth disorders that are often observed in childhood cancer survivors has been issued by the Endocrine Society and published in The Journal of Endocrinology and Metabolism.
Investigators note that the 5-year survival rates for childhood cancer are currently approximately 80%, but recent data indicate that 40% to 50% of survivors will develop an endocrine disorder at some point in their lives. While a large number of high-quality studies evaluating these issues have informed this guideline, most papers have focused on understanding the prevalence and risk factors for the various outcomes with fewer looking at diagnosis and patient management.